COVID-19 vaccine contender CureVac hyperlinks up with Bayer


A German firm that’s within the superior phases of manufacturing a vaccine in opposition to COVID-19 is linking up with pharmaceutical large Bayer to assist develop and distribute the product

BERLIN — A German firm that’s within the superior phases of manufacturing a vaccine in opposition to COVID-19 is linking up with pharmaceutical large Bayer to assist develop and distribute the product.

CureVac, primarily based within the German metropolis of Tuebingen, mentioned final month that it expects first outcomes the top of March from its section three scientific examine of the mRNA-based vaccine candidate referred to as CVnCoV.

Bayer will assist CureVac with nation operations within the European Union and “chosen extra markets” and holds choices to change into “advertising authorization holder” in different markets outdoors Europe, it mentioned.

It added that “the businesses plan to mix their strengths for CureVac to be ready to provide tons of of thousands and thousands of CVnCoV doses around the globe, as soon as approvals are granted.”

Germany’s state-owned KfW financial institution final yr took a 23% stake in CureVac.

One other German firm, BioNTech, developed the primary vaccine that was accepted to be used in Europe and the US, along with U.S. firm Pfizer. That vaccine can also be primarily based on mRNA expertise.



Supply hyperlink